Published in World J Surg on October 01, 2015
Can Positive Resection Margin of Intra-hepatic Cholangiocarcinoma Still Provide a Survival Benefit over Systemic Chemotherapy? World J Surg (2015) 0.77
Knockdown of Sall4 inhibits intrahepatic cholangiocarcinoma cell migration and invasion in ICC-9810 cells. Onco Targets Ther (2016) 0.75
Surgical options for intrahepatic cholangiocarcinoma. Hepatobiliary Surg Nutr (2017) 0.75
Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med (2010) 15.71
Recommendations for reporting cost-effectiveness analyses. Panel on Cost-Effectiveness in Health and Medicine. JAMA (1996) 8.52
The epidemiology of cholangiocarcinoma. Semin Liver Dis (2004) 5.59
Net health benefits: a new framework for the analysis of uncertainty in cost-effectiveness analysis. Med Decis Making (1998) 5.14
Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. Hepatology (2001) 5.12
Rising incidence of intrahepatic cholangiocarcinoma in the United States: a true increase? J Hepatol (2004) 4.39
Guidelines for the diagnosis and treatment of cholangiocarcinoma: consensus document. Gut (2002) 4.01
Assessing cost-effectiveness in healthcare: history of the $50,000 per QALY threshold. Expert Rev Pharmacoecon Outcomes Res (2008) 3.50
Intrahepatic cholangiocarcinoma: rising frequency, improved survival, and determinants of outcome after resection. Ann Surg (2008) 3.16
Intrahepatic cholangiocarcinoma: resectability, recurrence pattern, and outcomes. J Am Coll Surg (2001) 2.57
Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial. J Clin Oncol (2005) 2.52
Influence of surgical margins on outcome in patients with intrahepatic cholangiocarcinoma: a multicenter study by the AFC-IHCC-2009 study group. Ann Surg (2011) 2.42
Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study. Ann Oncol (2004) 2.39
Intrahepatic cholangiocarcinoma: management options and emerging therapies. J Am Coll Surg (2013) 2.22
Cholangiocarcinoma: modern advances in understanding a deadly old disease. J Hepatol (2006) 2.19
Intrahepatic cholangiocarcinoma: an international multi-institutional analysis of prognostic factors and lymph node assessment. J Clin Oncol (2011) 2.13
Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentre randomised phase II study - The UK ABC-01 Study. Br J Cancer (2009) 2.13
Cost-effectiveness analysis of liver resection versus transplantation for early hepatocellular carcinoma within the Milan criteria. Hepatology (2014) 2.11
Risk of hepatobiliary and pancreatic cancers after hepatitis C virus infection: A population-based study of U.S. veterans. Hepatology (2009) 1.80
A proposed staging system for intrahepatic cholangiocarcinoma. Ann Surg Oncol (2008) 1.64
Phase II study of systemic gemcitabine chemotherapy for advanced unresectable hepatobiliary carcinomas. Hepatogastroenterology (2001) 1.57
Is hepatic resection for large or multinodular hepatocellular carcinoma justified? Results from a multi-institutional database. Ann Surg Oncol (2005) 1.53
AJCC 7th edition of TNM staging accurately discriminates outcomes of patients with resectable intrahepatic cholangiocarcinoma: By the AFC-IHCC-2009 study group. Cancer (2010) 1.44
Natural History and Prognostic Factors of Advanced Cholangiocarcinoma without Surgery, Chemotherapy, or Radiotherapy: A Large-Scale Observational Study. Gut Liver (2009) 1.43
Two consecutive phase II studies of 5-fluorouracil/leucovorin/mitomycin C and of gemcitabine in patients with advanced biliary cancer. Oncology (1999) 1.38
Long-term survival and prognostic factors in the surgical treatment for intrahepatic cholangiocarcinoma. J Hepatobiliary Pancreat Surg (2003) 1.24
Review of gemcitabine in biliary tract carcinoma. Semin Oncol (2002) 1.15
A nomogram to predict long-term survival after resection for intrahepatic cholangiocarcinoma: an Eastern and Western experience. JAMA Surg (2014) 1.11
Treatment and Prognosis for Patients With Intrahepatic Cholangiocarcinoma: Systematic Review and Meta-analysis. JAMA Surg (2014) 1.10
Multidisciplinary approaches to intrahepatic cholangiocarcinoma. Cancer (2013) 1.08
Combination chemotherapy with gemcitabine and cisplatin as first-line treatment for immunohistochemically proven cholangiocarcinoma. Am J Clin Oncol (2006) 1.07
Major liver resection in elderly patients: a multi-institutional analysis. J Am Coll Surg (2011) 1.05
Surgical therapy for early hepatocellular carcinoma in the modern era: a 10-year SEER-medicare analysis. Ann Surg (2013) 1.04
Single-agent gemcitabine for biliary tract cancers. Study outcomes and systematic review of the literature. Oncology (2006) 1.03
A prospective longitudinal study of quality of life after resection of hepatocellular carcinoma. Arch Surg (2001) 1.01
Indications for surgical treatment of intrahepatic cholangiocarcinoma with lymph node metastases. J Hepatobiliary Pancreat Surg (2008) 0.94
Current status of chemotherapy for the treatment of advanced biliary tract cancer. Korean J Intern Med (2013) 0.92
Tumor size predicts vascular invasion and histologic grade among patients undergoing resection of intrahepatic cholangiocarcinoma. J Gastrointest Surg (2014) 0.88
Factors affecting survival after resection of intrahepatic cholangiocarcinoma. Surg Today (2014) 0.85
Identification of prognostic factors and the impact of palliative resection on survival of patients with stage IV hepatolithiasis-associated intrahepatic cholangiocarcinoma. J Surg Oncol (2013) 0.84
Hepatic resection vs minimally invasive radiofrequency ablation for the treatment of colorectal liver metastases: a Markov analysis. Arch Surg (2011) 0.84
Health-related quality of life: return to baseline after major and minor liver resection. Surgery (2007) 0.84
The impact of surgical treatment and poor prognostic factors for patients with intrahepatic cholangiocarcinoma: retrospective analysis of 60 patients. Anticancer Res (2008) 0.81
Temporal trends in liver-directed therapy of patients with intrahepatic cholangiocarcinoma in the United States: a population-based analysis. J Surg Oncol (2014) 0.81
Extended right hepatic lobectomy with resection of inferior vena cava and portal vein for intrahepatic cholangiocarcinoma. J Hepatobiliary Pancreat Surg (2000) 0.79
Boosted regression trees with errors in variables. Biometrics (2007) 0.78
Long-term survival of intrahepatic cholangiocarcinoma with hilar lymph node metastasis and portal vein involvement. Hepatogastroenterology (2005) 0.78
Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol (2006) 5.78
Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trial. J Clin Oncol (2011) 5.00
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. N Engl J Med (2014) 4.81
Inactivating mutations of the chromatin remodeling gene ARID2 in hepatocellular carcinoma. Nat Genet (2011) 4.38
Use of sorafenib in patients with hepatocellular carcinoma before liver transplantation: a cost-benefit analysis while awaiting data on sorafenib safety. Hepatology (2010) 3.53
Analysis of fluorouracil-based adjuvant chemotherapy and radiation after pancreaticoduodenectomy for ductal adenocarcinoma of the pancreas: results of a large, prospectively collected database at the Johns Hopkins Hospital. J Clin Oncol (2008) 3.51
Rates and patterns of recurrence following curative intent surgery for colorectal liver metastasis: an international multi-institutional analysis of 1669 patients. Ann Surg (2009) 3.15
Prospective validation of the Barcelona Clinic Liver Cancer staging system. J Hepatol (2006) 3.09
Phase II trial of sorafenib combined with concurrent transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma. J Clin Oncol (2011) 3.03
Human bile contains microRNA-laden extracellular vesicles that can be used for cholangiocarcinoma diagnosis. Hepatology (2014) 2.98
Selection of patients for resection of hepatic colorectal metastases: expert consensus statement. Ann Surg Oncol (2006) 2.66
Patient readmission and mortality after colorectal surgery for colon cancer: impact of length of stay relative to other clinical factors. J Am Coll Surg (2012) 2.29
Simultaneous resections of colorectal cancer and synchronous liver metastases: a multi-institutional analysis. Ann Surg Oncol (2007) 2.26
Intrahepatic cholangiocarcinoma: management options and emerging therapies. J Am Coll Surg (2013) 2.22
The critical issue of hepatocellular carcinoma prognostic classification: which is the best tool available? J Hepatol (2004) 2.18
When to perform hepatic resection for intermediate-stage hepatocellular carcinoma. Hepatology (2015) 2.15
Intrahepatic cholangiocarcinoma: an international multi-institutional analysis of prognostic factors and lymph node assessment. J Clin Oncol (2011) 2.13
Mutation of a single allele of the cancer susceptibility gene BRCA1 leads to genomic instability in human breast epithelial cells. Proc Natl Acad Sci U S A (2011) 2.12
Solitary colorectal liver metastasis: resection determines outcome. Arch Surg (2006) 2.06
Limitations of claims and registry data in surgical oncology research. Ann Surg Oncol (2007) 2.06
Knockin of mutant PIK3CA activates multiple oncogenic pathways. Proc Natl Acad Sci U S A (2009) 2.02
Is extended hepatectomy for hepatobiliary malignancy justified? Ann Surg (2004) 2.01
Pancreatic resection of isolated metastases from nonpancreatic primary cancers. Ann Surg Oncol (2008) 1.97
Incidence and prognostic impact of KRAS and BRAF mutation in patients undergoing liver surgery for colorectal metastases. Cancer (2013) 1.94
Impact of total lymph node count and lymph node ratio on staging and survival after pancreatectomy for pancreatic adenocarcinoma: a large, population-based analysis. Ann Surg Oncol (2007) 1.94
Liver transplantation for the treatment of moderately or well-differentiated hepatocellular carcinoma. Ann Surg (2004) 1.88
Trends in survival after surgery for cholangiocarcinoma: a 30-year population-based SEER database analysis. J Gastrointest Surg (2007) 1.87
Predictors of survival after resection of early hepatocellular carcinoma. Ann Surg (2009) 1.85
Sarcopenia negatively impacts short-term outcomes in patients undergoing hepatic resection for colorectal liver metastasis. HPB (Oxford) (2011) 1.82
Adjuvant chemoradiation for pancreatic adenocarcinoma: the Johns Hopkins Hospital-Mayo Clinic collaborative study. Ann Surg Oncol (2010) 1.79
Biology of hepatocellular carcinoma. Ann Surg Oncol (2008) 1.78
A single institution's 26-year experience with nonfunctional pancreatic neuroendocrine tumors: a validation of current staging systems and a new prognostic nomogram. Ann Surg (2014) 1.76
Operative mortality after hepatic resection: are literature-based rates broadly applicable? J Gastrointest Surg (2008) 1.69
Predictors of survival after resection of retroperitoneal sarcoma: a population-based analysis and critical appraisal of the AJCC staging system. Ann Surg (2009) 1.68
Surgical management of solid-pseudopapillary neoplasms of the pancreas (Franz or Hamoudi tumors): a large single-institutional series. J Am Coll Surg (2009) 1.67
Unresectable hepatocellular carcinoma: MR imaging after intraarterial therapy. Part II. Response stratification using volumetric functional criteria after intraarterial therapy. Radiology (2013) 1.66
A proposed staging system for intrahepatic cholangiocarcinoma. Ann Surg Oncol (2008) 1.64
Impact of sarcopenia on outcomes following resection of pancreatic adenocarcinoma. J Gastrointest Surg (2012) 1.64
Management of patients with pancreatic adenocarcinoma: national trends in patient selection, operative management, and use of adjuvant therapy. J Am Coll Surg (2011) 1.64
Adjuvant chemoradiation therapy for adenocarcinoma of the distal pancreas. Ann Surg Oncol (2010) 1.60
Predicting the risk of perioperative mortality in patients undergoing pancreaticoduodenectomy: a novel scoring system. Arch Surg (2011) 1.59
Pretreatment assessment of hepatocellular carcinoma: expert consensus statement. HPB (Oxford) (2010) 1.59
Informed consent and the surgeon. J Am Coll Surg (2009) 1.58
The impact of postoperative complications on the administration of adjuvant therapy following pancreaticoduodenectomy for adenocarcinoma. Ann Surg Oncol (2014) 1.58
Contrast-enhanced ultrasound and prostate cancer; a multicentre European research coordination project. Eur Urol (2008) 1.57
Histopathologic basis for the favorable survival after resection of intraductal papillary mucinous neoplasm-associated invasive adenocarcinoma of the pancreas. Ann Surg (2010) 1.56
Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma. Cancer (2014) 1.55
Early predictors of oxaliplatin-induced cumulative neuropathy in colorectal cancer patients. J Neurol Neurosurg Psychiatry (2013) 1.55
Patient readmission and mortality after surgery for hepato-pancreato-biliary malignancies. J Am Coll Surg (2012) 1.55
Is hepatic resection for large or multinodular hepatocellular carcinoma justified? Results from a multi-institutional database. Ann Surg Oncol (2005) 1.53
Impact of external-beam radiation therapy on outcomes among patients with resected gastric cancer: a multi-institutional analysis. Ann Surg Oncol (2014) 1.53
The survival benefit of liver transplantation in hepatocellular carcinoma patients. Dig Liver Dis (2010) 1.53
The volume-outcomes effect in hepato-pancreato-biliary surgery: hospital versus surgeon contributions and specificity of the relationship. J Am Coll Surg (2009) 1.52
Improving surgical outcomes through adoption of evidence-based process measures: intervention specific or associated with overall hospital quality? Surgery (2009) 1.51
Selection for hepatic resection of colorectal liver metastases: expert consensus statement. HPB (Oxford) (2013) 1.50
Treating patients with colon cancer liver metastasis: a nationwide analysis of therapeutic decision making. Ann Surg Oncol (2012) 1.50
Surgical management of hepatic neuroendocrine tumor metastasis: results from an international multi-institutional analysis. Ann Surg Oncol (2010) 1.50
Use of N-acetylcysteine during liver procurement: a prospective randomized controlled study. Liver Transpl (2012) 1.49
Contrast enhanced ultrasound in the detection of liver metastases: a prospective multi-centre dose testing study using a perfluorobutane microbubble contrast agent (NC100100). Eur Radiol (2011) 1.48
Assessing readmission after general, vascular, and thoracic surgery using ACS-NSQIP. Ann Surg (2013) 1.45
A multi-institution analysis of outcomes of liver-directed surgery for metastatic renal cell cancer. HPB (Oxford) (2012) 1.45
Liver cell adenoma: a multicenter analysis of risk factors for rupture and malignancy. Ann Surg Oncol (2009) 1.44
ACS-NSQIP has the potential to create an HPB-NSQIP option. HPB (Oxford) (2009) 1.44
Management and recurrence patterns of desmoids tumors: a multi-institutional analysis of 211 patients. Ann Surg Oncol (2012) 1.44
Refining the definition of perioperative mortality following hepatectomy using death within 90 days as the standard criterion. HPB (Oxford) (2011) 1.44
Conditional survival in patients with pancreatic ductal adenocarcinoma resected with curative intent. Cancer (2011) 1.43
Evolving treatment strategies for gallbladder cancer. Ann Surg Oncol (2009) 1.42
Repeat curative intent liver surgery is safe and effective for recurrent colorectal liver metastasis: results from an international multi-institutional analysis. J Gastrointest Surg (2009) 1.41
Liver transplantation using suboptimal grafts: impact of donor harvesting technique. Liver Transpl (2007) 1.41
Skin cancer and other cutaneous disorders in liver transplant recipients. Acta Derm Venereol (2012) 1.41
Trends in the quality of highly cited surgical research over the past 20 years. Ann Surg (2009) 1.41
Male breast cancer: clinical features and multimodal treatment in a retrospective survey analysis at Italian centers. Tumori (2013) 1.39
Conditional survival after surgical resection of colorectal liver metastasis: an international multi-institutional analysis of 949 patients. J Am Coll Surg (2010) 1.37
Identification of the protein storage vacuole and protein targeting to the vacuole in leaf cells of three plant species. Plant Physiol (2004) 1.36
National trends in the management and survival of surgically managed gallbladder adenocarcinoma over 15 years: a population-based analysis. J Gastrointest Surg (2010) 1.36
Clinicopathologic analysis of ampullary neoplasms in 450 patients: implications for surgical strategy and long-term prognosis. J Gastrointest Surg (2010) 1.33
Colorectal liver metastases: recurrence and survival following hepatic resection, radiofrequency ablation, and combined resection-radiofrequency ablation. Arch Surg (2008) 1.32
Surgery versus intra-arterial therapy for neuroendocrine liver metastasis: a multicenter international analysis. Ann Surg Oncol (2011) 1.31
Choledochal cyst disease in children and adults: a 30-year single-institution experience. J Am Coll Surg (2008) 1.29
Intrahepatic cholangiocarcinoma. Surg Clin North Am (2010) 1.27
Acinar cell carcinoma of the pancreas: an institutional series of resected patients and review of the current literature. J Gastrointest Surg (2007) 1.26
A systematic review: treatment and prognosis of patients with fibrolamellar hepatocellular carcinoma. J Am Coll Surg (2012) 1.26
Duodenal adenocarcinoma: clinicopathologic analysis and implications for treatment. Ann Surg Oncol (2011) 1.24
Incidence and management of chyle leaks following pancreatic resection: a high volume single-center institutional experience. J Gastrointest Surg (2008) 1.23
Determining pattern of recurrence following pancreaticoduodenectomy and adjuvant 5-flurouracil-based chemoradiation therapy: effect of number of metastatic lymph nodes and lymph node ratio. J Gastrointest Surg (2008) 1.22
Total pancreatectomy for pancreatic adenocarcinoma: evaluation of morbidity and long-term survival. Ann Surg (2009) 1.22
Randomized phase III multi-institutional study of TNFerade biologic with fluorouracil and radiotherapy for locally advanced pancreatic cancer: final results. J Clin Oncol (2013) 1.22
MicroRNA down-regulated in human cholangiocarcinoma control cell cycle through multiple targets involved in the G1/S checkpoint. Hepatology (2011) 1.22
Comparison between hepatic wedge resection and anatomic resection for colorectal liver metastases. J Gastrointest Surg (2006) 1.22
Phase I dose-escalation study of AZD7762, a checkpoint kinase inhibitor, in combination with gemcitabine in US patients with advanced solid tumors. Cancer Chemother Pharmacol (2014) 1.20
Variation in lymph node assessment after colon cancer resection: patient, surgeon, pathologist, or hospital? J Gastrointest Surg (2010) 1.20
Volume-based trends in thyroid surgery. Arch Otolaryngol Head Neck Surg (2010) 1.19
Disappearing colorectal liver metastases after chemotherapy: should we be concerned? J Gastrointest Surg (2010) 1.19
Shifting trends in liver-directed management of patients with colorectal liver metastasis: a population-based analysis. Surgery (2011) 1.17
Zeolin. A new recombinant storage protein constructed using maize gamma-zein and bean phaseolin. Plant Physiol (2004) 1.17
The impact of portal vein resection on outcomes for hilar cholangiocarcinoma: a multi-institutional analysis of 305 cases. Cancer (2012) 1.16
Nodal status, number of lymph nodes examined, and lymph node ratio: what defines prognosis after resection of colon adenocarcinoma? J Am Coll Surg (2013) 1.16
Liver resection for colorectal metastases in presence of extrahepatic disease: results from an international multi-institutional analysis. Ann Surg Oncol (2010) 1.16